Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Jennifer K. Litton; Hope S. Rugo; Johannes Ettl; Sara A. Hurvitz; Anthony Gonçalvès; Kyung-Hun Lee; Louis Fehrenbacher; Rinat Yerushalmi; Lida A. Mina; Miguel Martín; Henri Roché; Young‐Hyuck Im; Ruben G.W. Quek; Denka Markova; Iulia Cristina Tudor; Alison L. Hannah; W. Eiermann; Joanne L. Blum

doi:10.1056/nejmoa1802905

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Litton et al. (2018) studied this question.

synapsesocial.com/papers/69d8f8102c39562886ae3874 https://doi.org/10.1056/nejmoa1802905

View Full Paper

Ask AI

Bookmark

Share

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Ask about this paper

Abstract

Discussion

Cite This Study

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading